Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Baseline demographics and patient characteristics

From: Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients

Characteristic CZP ITT population (n = 492) Week 24 CZP completers (n = 342) Week 24 placebo completers (n = 17) Dose-reduction population (n = 369) Safety population (n = 612)
Age, mean (SD), years 52.0 (11.4) 51.6 (11.6) 53.2 (16.0) 51.1 (11.3) 51.9 (11.5)
Gender, % female 80.9 82.7 82.4 81.8 81.5
Disease duration, mean (SD), years 6.3 (4.2) 6.5 (4.2) 3.5 (2.3) 6.2 (4.2) 6.2 (4.2)
RF-positive (≥14 IU/ml), % 76.5 75.4 88.2 73.7 76.9
Tender/painful joint count, mean (SD) 30.1 (14.2) 30.5 (14.5) 33.4 (12.1) 29.9 (13.9) 30.2 (14.0)
Swollen joint count, mean (SD) 20.7 (9.9) 20.7 (10.1) 24.2 (8.2) 20.6 (10.1) 21.0 (9.9)
Pain VAS, mean (SD) 61.2 (19.7) 60.6 (19.8)a 59.1 (21.6) 61.2 (19.5)b 60.9 (20.3)c
HAQ-DI, mean (SD) 1.6 (0.6) 1.6 (0.6) 1.6 (0.5) 1.6(0.6) 1.6 (0.6)d
DAS28(ESR), median (min, max) 6.8 (4, 9)e 6.8 (5, 9)a 7.1 (6, 8) 6.8 (5, 9)b 6.9 (4, 9)f
  1. an = 340; bn = 367; cn = 610; dn = 611; en = 490; fn = 608. CZP certolizumab pegol, ITT intention-to-treat; RF rheumatoid factor, VAS visual analog scale, HAQ-DI health assessment questionnaire-disability index, DAS28 disease activity score 28, ESR erythrocyte sedimentation rate